Biotech Values

[DewDiligence]

I wonder whether the FDA's recommendations [for Xarelto] would have been different if apixaban was not in the picture.

The better question, IMO, is whether the FDA’s opinion of Xarelto in AF would have been different if neither Eliquis (apixaban) nor Pradaxa were in the picture. I think the answer is no, FWIW.